{"id":740177,"date":"2023-03-15T07:05:41","date_gmt":"2023-03-15T11:05:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/"},"modified":"2023-03-15T07:05:41","modified_gmt":"2023-03-15T11:05:41","slug":"medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/","title":{"rendered":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO\u00a0and\u00a0HOUSTON, March  15, 2023  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023.<\/p>\n<p>The full text of the published abstract can be found on the AACR Annual Meeting website. Details on the corresponding poster are shown below.<\/p>\n<p>\n        <strong>Poster Title: <\/strong>Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment<\/p>\n<p>\n        <strong>Session Category: <\/strong>Immunology<\/p>\n<p>\n        <strong>Session Title: <\/strong>Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies<\/p>\n<p>\n        <strong>Session Date and Time: <\/strong>April 16, 2023; 1:30 pm \u2013 5:00 pm ET<\/p>\n<p>\n        <strong>Abstract Number: <\/strong>708<\/p>\n<p align=\"justify\">The poster will describe preclinical studies characterizing a long-acting version of MDNA132 and BiSKITs\u2122, (<strong>Bi<\/strong>functional <strong>S<\/strong>uper<strong>K<\/strong>ine <strong>I<\/strong>mmuno<strong>T<\/strong>herapies) comprising MDNA132 fused to an IL-2 super-agonist or anti-PD1 antibody. MDNA132 is an IL-13 Superkine designed to enable targeted delivery of immunotherapies to the tumor microenvironment. MDNA132 exhibits high affinity and selectivity for the IL13R\u03b12, which is highly overexpressed in various tumors such as pancreatic, prostate, bladder, colorectal, breast and lung cancer but minimally expressed in healthy tissues.<\/p>\n<p>Following the conclusion of the AACR Meeting, a copy of the poster will be available on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DS5jhL3W299e4DjUQiaXomOOuq01xKK2cPksUFx13G6yKUBQ7CC8Tbw_MNB0IxDKfbCaFJ2wLtwGWsiG38iTFjQXpwvrkiBKmg0Ejgzc0y32XaTILJEwdEgZ-0RToCKwTlUa_0GgP7u0lPhoqF66gjx-FCm-9kCtpc9e47VpK2goFHqlHdboB2U0GYpHysB6y_xSVcumFZaUzFfuAnASBjpSnFoHrmWuYChSqfH-4VoovRfRfYxe3GPSXDnEjvC_pWL91MAtySTBWbtZFWEaeILBxE8lJCOmz6o7CTL1VUOtYTGBX9PY4vQoZpfrOWsVXmAbe5ZMpy0EdaZMWLwW6uXqlYqJMvpDdi7ZIXuXHM3V5MOQQuIswHZqN_UqwSx8objsISsSIytg69qyl1B6miOaB-4azXnJXw_DoPSx3ad3CRAqIr8oX4HtIm613NmdelD5QS5A5WxghIFRobp1iR3cqDDBk3VOMbKZrIyd2EChBS0WalMMWK_2B2cwh4ZHUl6paH02vmA3FYGuRTMSwvWitObUd7CtjRnALPCLfmx7_4yguZdMnUPKZ4FqOZYC7R6wf9bFeFVCgMBII9nh_g==\" rel=\"nofollow noopener\" target=\"_blank\">Events and\u00a0Presentations<\/a>\u201d page of Medicenna\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About Medicenna<\/strong><br \/>\n        <br \/>Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna\u2019s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna\u2019s early-stage BiSKITs\u2122 program, (<strong>Bi<\/strong>functional\u00a0<strong>S<\/strong>uper<strong>K<\/strong>ine\u00a0<strong>I<\/strong>mmuno<strong>T<\/strong>herapies) is designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors. Medicenna\u2019s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cbelieve\u201d, \u201cseek\u201d, \u201cpotentially\u201d and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in\u00a0Canada\u00a0and\u00a0the\u00a0United States.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.<\/em>\n      <\/p>\n<p>\n        <strong>Further Information<\/strong>\n      <\/p>\n<p>For further information about the Company please contact:<\/p>\n<p>Elizabeth Williams, Chief Financial Officer, 416-648-5555, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nVYHPdhS8IdgjceUaU-hsHSvbEcEnnLZcdOBH58toeSDUVqBLSy5r1F6j2VwL3k0qwHcB8wgnVfVty8Ic24nIiCjg9mLnGvItbJduYmBROA=\" rel=\"nofollow noopener\" target=\"_blank\">ewilliams@medicenna.com<\/a>\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p>For more investor information, please contact:<\/p>\n<p>Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0csXUqQ5dUG6sUsIMpkMVzHUCohzW-ZRE6ZcOlL4IpAPx2-b3DoAAFbhW5VGYCYKlRZChqGwPlME2TWGMWNfiZ7oMYNM03e6pIZ5yzOoDoHQpsYqQhjDS2pymMJqZVMj\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com\u00a0<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDFmZGQwNWEtNGVjMC00NTIyLWFlZjEtZjExMjc0ODU4MGJjLTExMzQwNTI=\/tiny\/Medicenna-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO\u00a0and\u00a0HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full text of the published abstract can be found on the AACR Annual Meeting website. Details on the corresponding poster are shown below. Poster Title: Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment Session Category: Immunology Session Title: Oncolytic Viruses, Anticancer Vaccines, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medicenna Announces Upcoming Presentation at the AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740177","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO\u00a0and\u00a0HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full text of the published abstract can be found on the AACR Annual Meeting website. Details on the corresponding poster are shown below. Poster Title: Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment Session Category: Immunology Session Title: Oncolytic Viruses, Anticancer Vaccines, and &hellip; Continue reading &quot;Medicenna Announces Upcoming Presentation at the AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T11:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting\",\"datePublished\":\"2023-03-15T11:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/\",\"name\":\"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\",\"datePublished\":\"2023-03-15T11:05:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk","og_description":"TORONTO\u00a0and\u00a0HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp.\u00a0(\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 \u2013 19, 2023. The full text of the published abstract can be found on the AACR Annual Meeting website. Details on the corresponding poster are shown below. Poster Title: Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment Session Category: Immunology Session Title: Oncolytic Viruses, Anticancer Vaccines, and &hellip; Continue reading \"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-15T11:05:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting","datePublished":"2023-03-15T11:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/","name":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=","datePublished":"2023-03-15T11:05:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjE0MSM1NDU1ODQyIzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-announces-upcoming-presentation-at-the-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Announces Upcoming Presentation at the AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740177"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}